OKYO Pharma (OKYO) director awarded 5,000 common shares at $1.4770
Rhea-AI Filing Summary
OKYO Pharma Ltd director John P Brancaccio reported a grant of 5000 shares of common stock on 2026-07-21. The award, coded as a “grant, award, or other acquisition,” was priced at $1.4770 per share and increased his direct holdings to 35201 shares. The filing’s Rule 10b5-1 checkbox was not marked as being under a trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 5,000 shares
Net Buy
1 txn
Insider
BRANCACCIO JOHN P
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | COMMON STOCK | 5,000 | $1.477 | $7K |
Holdings After Transaction:
COMMON STOCK — 35,201 shares (Direct)
Key Figures
Shares acquired: 5000.0000 shares
Grant price per share: $1.4770
Shares owned after transaction: 35201.0000 shares
3 metrics
Shares acquired
5000.0000 shares
Grant of common stock on 2026-07-21
Grant price per share
$1.4770
Value assigned to the common stock award
Shares owned after transaction
35201.0000 shares
Direct holdings following the reported grant
Key Terms
Form 4, Grant, award, or other acquisition, non-derivative, Rule 10b5-1
4 terms
Form 4 regulatory
"The director’s equity award is reported on <b>Form 4</b>."
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Grant, award, or other acquisition regulatory
"The transaction code description is <b>Grant, award, or other acquisition</b>."
non-derivative financial
"The common stock is classified as a <b>non-derivative</b> security in the filing."
Rule 10b5-1 regulatory
"A checkbox indicates whether trades are under a <b>Rule 10b5-1</b> plan."
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did OKYO (OKYO) director John P Brancaccio report?
John P Brancaccio reported a grant of 5000 common shares of OKYO Pharma Ltd on 2026-07-21 at $1.4770 per share. This award increased his direct ownership position to 35201 shares of OKYO common stock.
Was the OKYO (OKYO) Form 4 transaction made under a Rule 10b5-1 plan?
The Form 4 indicates the transaction was not affirmed under a Rule 10b5-1 plan, as the related checkbox is not marked. This means the reported stock grant is not disclosed as part of a pre-arranged trading plan.
What type of security is involved in the latest OKYO (OKYO) Form 4 filing?
The transaction involves common stock classified as a non-derivative security. The Form 4 reports a direct acquisition of 5000 shares, rather than options or other derivative instruments, and updates the director’s common stock holdings accordingly.
Is the OKYO (OKYO) Form 4 transaction a market purchase or an equity award?
The transaction is coded “A” as a grant, award, or other acquisition, indicating an equity award rather than an open-market purchase. The director received 5000 shares at a stated value of $1.4770 per share, increasing his direct holdings.